Epithelial Ovarian Cancer Drugs Market is segmented By Drug type (Carboplatin-taxon, Gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors, Others), By Distribution channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Epithelial Ovarian Cancer Drugs Market Overview
Epithelial ovarian cancer drugs market size was valued at USD million in 2022 and is estimated to reach USD million by 2031, growing at a high CAGR during the forecast period 2024-2031.
Ovarian cancer is the type of cancer that affects the ovaries in the female reproductive system. Epithelial ovarian cancer is the most prevalent type of ovarian cancer. About 90 out of 100 tumors of the ovary (90%) are epithelial. Epithelial ovarian cancer means cancer started in the surface layer covering the ovary. It is a disease in which the malignant cells develop in the tissue that covers the ovary. It is common in women with a close relation, such as mother, daughter, or sister diagnosed with the disease. In women having two or more blood relatives with ovarian cancer, the risk of developing the disease is higher. The genetic information is carried from one generation to another generation through carrier genes received from parents and, the risk of developing ovarian cancer is very high in a woman who has inherited mutations in the BRCA1 and BRCA2 genes. It has been estimated that hereditary ovarian cancer is nearly 5% - 10% more prevalent when compared to other cases of ovarian cancer. Some symptoms of epithelial ovarian cancer include pain in the pelvis area, swelling in the abdomen, and gastrointestinal problems such as bloating. Epithelial ovarian cancer is diagnosed through a series of procedures such as pelvic examination, ultrasound, CA 125 assay, barium enema, intravenous pyelogram (IVP), CT scan, and biopsy. The treatment for epithelial ovarian cancer includes chemotherapy drugs, targeted therapy drugs, surgery, radiation therapy.
Epithelial Ovarian Cancer Drugs Market Scope
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Drug Type, By Distributional Channels, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Epithelial Ovarian Cancer Drugs Market Dynamics
The global epithelial ovarian cancer drugs market growth is driven by the growing incidences of ovarian cancer, rise in research and development activities, major market players that are currently undergoing the development of drugs and chemotherapies to manage ovarian cancer and growing government initiatives to promote awareness about the disease are projected to drive the epithelial ovarian cancer market during the forecast period.
Growing incidence of ovarian cancer cases, is expected to drive the growth in the forecast period
Ovarian cancer is the fifth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a World Ovarian Cancer Coalition study, an estimated 55% rise is expected in the number of patients who have ovarian cancer by 2035. About 90 out of 100 tumors of the ovary (90%) are epithelial. According to the Cancer Statistics in 2020, published by the American Cancer Society, about 1,806,590 new cancer cases were diagnosed in 2021, about 21,410 women will receive a new diagnosis of ovarian cancer.
Strong pipeline of Epithelial ovarian cancer drugs, is expected to drive the growth in the forecast period
University of Pennsylvania Collaborated with AstraZeneca developing a Combination ATR and PARP Inhibitor (CAPRI) with AZD 6738 and Olaparib in treating patients with high grade serous ovarian Carcinoma type of epithelial ovarian cancer is under Phase 2 clinical trial.
AstraZeneca collaborated with Myriad Genetic Laboratories, Inc conducting a Phase 3 study of Durvalumab in Combination with Chemotherapy and Bevacizumab, followed by maintenance of Durvalumab, Bevacizumab and Olaparib in newly diagnosed Advanced Ovarian Cancer Patients.
Increased usage of biologics and targeted therapies is likely to hamper the global Epithelial Ovarian Cancer drugs market.
The targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroy normal cells. For instance, Bevacizumab is a targeted therapy biologics drug used to treat Ovarian Cancer. A targeted therapy drug, Zejula, was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in the drug pipeline. The FDA has also approved Genentech’s biologics license for ovarian cancer drugs, highlighting that many new players enter the biologics ovarian drug cancer market. Hence, the rising demand for alternatives such as biologics and targeted therapies may restrict the growth of the epithelial ovarian cancer drug market.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global Colorectal Cancer drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Epithelial Ovarian Cancer Drugs Market Segmentation Analysis
Based on the Drug Type, the global epithelial ovarian cancer drugs market is segmented into Carboplatin-taxon, gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors and others
Carboplatin-Taxon, Gemcitabine-Cisplatin segments are expected to grow at the fastest CAGR during the forecast period (2023-2030)
The combination drugs consist of two or more active pharmaceutical ingredients (APIs) combined into a single dosage form to treat critical medical conditions. Many pharmaceutical companies in the ovarian cancer drugs market invest in the R&D of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficacy, improve medication concordance, increase profitability and reduce side effects. Combination therapy of gemcitabine with a platinum compounds produced high response rates (as high as 71%) in patients with ovarian cancer. Popular combinations include gemcitabine with a platinum compound and paclitaxel and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for treating epithelial ovarian cancer includes a combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere). For example, Roche's blockbuster tranquilize Avastin (bevacizumab) is a combination drug approved by the FDA, with ingredients such as carboplatin and paclitaxel utilized to treat advanced stage (III or IV) ovarian cancer.
Based on the distribution channel, the global Epithelial Ovarian Cancer Drugs market is segmented into hospital pharmacies, Retail pharmacies, Online pharmacies and Others.
The hospital pharmacy are expected to dominate the Epithelial Ovarian Cancer Drugs market during the forecast period
The hospital pharmacies held the largest share in the epithelial ovarian cancer drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Global Epithelial Ovarian Cancer Drugs Market Geographical Share
North America holds the largest market in the global epithelial ovarian cancer drugs market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. According to the National Cancer Institute, in U.S., 22,240 new cases were diagnosed with ovarian cancer. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations.
Epithelial Ovarian Cancer Drugs Market Companies and Competitive Landscape
The global epithelial ovarian cancer drugs market is quite competitive with some key competitors like AstraZeneca, Roche, Tesaro, Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc., Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Oasmia Pharmaceutical AB. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market’s growth globally. For instance, Hoffmann-La Roche- An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front-Line Management of Advanced/Metastatic Epithelial Ovarian Cancer.
Tesaro
Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer. Tesaro was founded in 2010 and headquartered in Waltham, Massachusetts, USA. In January 2019, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, acquired Tesaro for $5.1 billion. This acquisition would enable GSK to expand its product portfolio with Tesaro’s Zejula, PARP inhibitor and others, improve significant opportunities in strengthening GSK’s pharmaceutical business by accelerating the build of GSK’s pipeline and commercial capability in oncology.
Key developments:
GSK3985771 †niraparib (Zejula) is under phase 3 clinical trials Ovarian cancer 1L maintenance combo with dostarlimab.
Why Purchase the Report?
- Visualize the composition of the epithelial ovarian cancer drugs market segmentation by drug type, by distribution channel, and region highlighting the key commercial assets and players.
- Identify commercial opportunities in epithelial ovarian cancer drugs market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of epithelial ovarian cancer drugs market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global epithelial ovarian cancer drugs market report would provide an access to an approx. 50 market data table, 44 figures and 240 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
